Published in J Clin Invest on November 01, 2001
Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest (2005) 5.53
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30
Isoprenoids as mediators of the biological effects of statins. J Clin Invest (2002) 2.19
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation (2005) 2.09
Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A (2006) 2.02
Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res (2007) 1.73
Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation (2010) 1.61
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34
Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J (2004) 1.31
Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest (2006) 1.31
Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart (2005) 1.26
NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond B Biol Sci (2005) 1.17
Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med (2010) 1.15
Rad GTPase deficiency leads to cardiac hypertrophy. Circulation (2007) 1.15
Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res (2006) 1.13
Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep (2003) 1.11
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin (2010) 1.05
Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol (2013) 1.01
Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice. Circulation (2013) 1.01
Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol (2010) 1.00
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.98
A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med (2003) 0.97
FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J (2012) 0.95
Long-term administration of tempol attenuates postinfarct ventricular dysfunction and sympathetic activity in rats. Pflugers Arch (2009) 0.94
Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One (2014) 0.93
Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases. Int J Mol Sci (2015) 0.91
miR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity. PLoS One (2014) 0.90
Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.90
Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag (2005) 0.89
The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase. BMC Biotechnol (2013) 0.89
Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2009) 0.88
The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats. J Cell Mol Med (2012) 0.88
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Animal models of cardiac disease and stem cell therapy. Open Cardiovasc Med J (2010) 0.88
Interleukin-18 enhances IL-18R/Nox1 binding, and mediates TRAF3IP2-dependent smooth muscle cell migration. Inhibition by simvastatin. Cell Signal (2013) 0.87
AAV-based RNAi silencing of NADPH oxidase gp91(phox) attenuates cold-induced cardiovascular dysfunction. Hum Gene Ther (2012) 0.87
Statins in the treatment of chronic heart failure: a systematic review. PLoS Med (2006) 0.85
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.85
Statin therapy for cardiac hypertrophy and heart failure. J Investig Med (2004) 0.85
Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med (2009) 0.85
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol (2013) 0.83
Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol (2004) 0.83
Orphan Nuclear Receptor Nur77 Inhibits Cardiac Hypertrophic Response to Beta-Adrenergic Stimulation. Mol Cell Biol (2015) 0.83
Lovastatin-enriched rice straw enhances biomass quality and suppresses ruminal methanogenesis. Biomed Res Int (2013) 0.82
Lesions and lipids and radicals--O my! Tex Heart Inst J (2004) 0.81
Cardiac hypertrophy and oxidative stress: a leap of faith or stark reality? Heart (2002) 0.80
Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.80
Heart failure and statins--why do we need a clinical trial? Z Kardiol (2005) 0.80
Statins and the myocardium. Semin Vasc Med (2004) 0.79
Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature. Heart Vessels (2013) 0.79
Enhanced nanomagnetic gene transfection of human prenatal cardiac progenitor cells and adult cardiomyocytes. PLoS One (2013) 0.79
Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons. ISRN Neurol (2011) 0.78
Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro. Clin Exp Immunol (2014) 0.78
Effects of statins on cardiorenal syndrome. Int J Vasc Med (2012) 0.78
Effects of antioxidant vitamins along with atorvastatin and atorvastatin-niacin combination on diet-induced hypercholesterolemia in rats. Int J Physiol Pathophysiol Pharmacol (2010) 0.78
Applying harmonic optical microscopy for spatial alignment of atrial collagen fibers. PLoS One (2010) 0.77
Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab (2010) 0.77
Cardiomyocyte H9c2 Cells Exhibit Differential Sensitivity to Intracellular Reactive Oxygen Species Generation with Regard to Their Hypertrophic vs Death Responses to Exogenously Added Hydrogen Peroxide. J Clin Biochem Nutr (2009) 0.76
Rac1 and connective tissue growth factor. The missing link between atrial remodeling and the pathogenesis of atrial fibrillation? J Am Coll Cardiol (2010) 0.76
Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. Heart Vessels (2015) 0.76
Reactive Oxygen Species: A Key Hallmark of Cardiovascular Disease. Adv Med (2016) 0.76
Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. Nagoya J Med Sci (2011) 0.75
Fn14 is regulated via the RhoA pathway and mediates nuclear factor-kappaB activation by Angiotensin II. Am J Transl Res (2016) 0.75
Regulation of PUMA induced by mechanical stress in rat cardiomyocytes. J Biomed Sci (2012) 0.75
Statins and myocardial hypertrophy. Coron Artery Dis (2004) 0.75
HERPUD1 protects against oxidative stress-induced apoptosis through downregulation of the inositol 1,4,5-trisphosphate receptor. Free Radic Biol Med (2015) 0.75
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Curr Heart Fail Rep (2017) 0.75
Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4. Clin Exp Nephrol (2016) 0.75
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell (1992) 28.36
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell (1995) 24.99
Regulation of the mevalonate pathway. Nature (1990) 18.25
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) Science (1996) 15.88
Rho GTPases and signaling networks. Genes Dev (1997) 11.70
Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation (2000) 7.12
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 5.11
Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest (1993) 4.70
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science (1991) 3.87
The role of iron in the activation-inactivation of aconitase. J Biol Chem (1983) 3.42
Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J (1991) 3.29
Protein lipidation in cell signaling. Science (1995) 3.22
Inactivation-reactivation of aconitase in Escherichia coli. A sensitive measure of superoxide radical. J Biol Chem (1992) 2.60
RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest (1999) 2.51
Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J (1996) 2.31
Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23
Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation (1998) 2.05
Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest (1998) 1.96
HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem (1993) 1.91
Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest (1999) 1.82
Bacterial toxins that target Rho proteins. J Clin Invest (1997) 1.69
Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A (1998) 1.68
Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation (1998) 1.57
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol (2001) 1.51
Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med (1999) 1.49
Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem (1996) 1.48
Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res (1998) 1.46
Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol (1986) 1.46
The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem (1998) 1.40
Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension (1995) 1.32
The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med (1996) 1.28
A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest (1998) 1.27
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol (1999) 1.17
Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A (1992) 1.15
Preproenkephalin mRNA expression in developing rat heart and in cultured ventricular cardiac muscle cells. Biochem J (1989) 1.04
Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res (1999) 1.01
Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol (1998) 0.98
Long-term culture of contractile mammalian heart cells in a defined serum-free medium that limits non-muscle cell proliferation. J Mol Cell Cardiol (1984) 0.94
Signaling pathways for cardiac growth and hypertrophy. Recent advances and prospects for growth factor therapy. Ann N Y Acad Sci (1995) 0.92
ADP-ribosylation of Rho proteins by Clostridium botulinum exoenzyme C3 is influenced by phosphorylation of Rho-associated factors. Biochem J (1994) 0.90
Cardiac hypertrophy in hypertension. N Engl J Med (1987) 0.89
Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (1999) 7.13
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol (2001) 6.43
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol (2001) 5.82
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 5.11
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (2000) 4.92
Self-reported health status and mortality in a multiethnic US cohort. Am J Epidemiol (1999) 4.45
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol (2001) 3.65
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Nucleotide sequence of the hag gene encoding flagellin of Escherichia coli. J Bacteriol (1986) 2.68
Chemical mapping of a single molecule by plasmon-enhanced Raman scattering. Nature (2013) 2.19
Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology (1993) 2.15
Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation (2000) 2.14
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem (1997) 2.12
Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem (1995) 2.11
Is hypertension more severe among U.S. blacks, or is severe hypertension more common? Ann Epidemiol (1996) 2.09
Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc (2001) 2.06
Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg (1993) 2.06
Determinants of incident non-insulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol (1993) 2.04
Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA (1999) 2.00
Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem (2001) 1.97
VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci (1999) 1.89
Fatty acid modulation of endothelial activation. Am J Clin Nutr (2000) 1.81
Intracellular free calcium concentration measured with 19F NMR spectroscopy in intact ferret hearts. Proc Natl Acad Sci U S A (1987) 1.80
Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest (2000) 1.76
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem (1999) 1.76
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A (1987) 1.72
Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth (2007) 1.70
Misreading of termination codons in eukaryotes by natural nonsense suppressor tRNAs. Nucleic Acids Res (2001) 1.68
The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med (1992) 1.67
Acute promyelocytic leukemia with marrow fibrosis at initial presentation: possible involvement of transforming growth factor-beta(1). Acta Haematol (2000) 1.66
All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood (1995) 1.66
Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol (2001) 1.64
Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic americans. Ann Epidemiol (2000) 1.63
Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. Circulation (1991) 1.60
Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". J Am Coll Cardiol (1995) 1.54
Extracorporeal membrane oxygenation for graft failure after heart transplantation: recent Vienna experience. J Thorac Cardiovasc Surg (2001) 1.52
Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus (2012) 1.50
Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation. Clin Exp Allergy (2010) 1.47
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke (2001) 1.47
Different mechanisms of ischemic adaptation to repeated coronary occlusion in patients with and without recruitable collateral circulation. J Am Coll Cardiol (1997) 1.47
Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol (1998) 1.46
Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation. Mamm Genome (1998) 1.44
[New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr (1997) 1.42
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation (2000) 1.41
Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol (1995) 1.41
Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation (2001) 1.41
Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. Circulation (1997) 1.40
Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts. Cardiovasc Drugs Ther (2001) 1.39
Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther (2000) 1.39
Cell cycle regulation of cyclin-dependent kinases in tobacco cultivar Bright Yellow-2 cells. Plant Physiol (2001) 1.38
Targeting Rho in cardiovascular disease. Circ Res (2000) 1.38
Mortality and optimal body mass index in a sample of the US population. Am J Epidemiol (1998) 1.37
Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery (1987) 1.35
Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol (1995) 1.34
Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med (1979) 1.30
The relation between income and mortality in U.S. blacks and whites. Epidemiology (1998) 1.29
Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension (2001) 1.28
Quantification of [Ca2+]i in perfused hearts. Critical evaluation of the 5F-BAPTA and nuclear magnetic resonance method as applied to the study of ischemia and reperfusion. Circ Res (1990) 1.27
Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol (1986) 1.26
Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol (1998) 1.26
The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy (2010) 1.26
Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation (1998) 1.25
Elevation of the plasma histamine concentration in the coronary circulation in patients with variant angina. Am J Cardiol (1996) 1.25
Effect of crystallinity of microcrystalline cellulose on the compactability and dissolution of tablets. Eur J Pharm Biopharm (1999) 1.24
Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem (1997) 1.24
Prostatic levels of tocopherols, carotenoids, and retinol in relation to plasma levels and self-reported usual dietary intake. Am J Epidemiol (2000) 1.24
Role of the CDC25 homology domain of phospholipase Cepsilon in amplification of Rap1-dependent signaling. J Biol Chem (2001) 1.23
Relative weight and mortality in U.S. blacks and whites: findings from representative national population samples. Ann Epidemiol (1997) 1.23
Identification of PLC210, a Caenorhabditis elegans phospholipase C, as a putative effector of Ras. J Biol Chem (1998) 1.22
Unexpected complication resulting from peritoneal dialysis catheter break. Perit Dial Int (1999) 1.22
A functional role of I kappa B-epsilon in endothelial cell activation. J Immunol (2000) 1.19
Regulation of myogenic terminal differentiation by the hairy-related transcription factor CHF2. J Biol Chem (2001) 1.19
Limit on neutrinoless ββ decay of 136Xe from the first phase of KamLAND-Zen and comparison with the positive claim in 76Ge. Phys Rev Lett (2013) 1.18
Isolation and characterization of the E2F-like gene in plants. FEBS Lett (1999) 1.17
Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation (1999) 1.16
Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther (2001) 1.16
Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem (1999) 1.15
Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation (2000) 1.15
Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab (2000) 1.15
Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg (2000) 1.13
Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res (2006) 1.13
Adenosine, the heart, and coronary circulation. Hypertension (1991) 1.13
Mathematic modeling of forces associated with shoulder dystocia: a comparison of endogenous and exogenous sources. Am J Obstet Gynecol (2000) 1.13
Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension (2000) 1.13
Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels. Circulation (1997) 1.12
Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res (2000) 1.12
Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther (2001) 1.12
Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res (2000) 1.11
Asymmetric total synthesis of halicholactone. J Org Chem (2001) 1.09
Aberrant TCR-mediated signaling in CD45-null thymocytes involves dysfunctional regulation of Lck, Fyn, TCR-zeta, and ZAP-70. J Immunol (1997) 1.09
Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol (2001) 1.08
Sex differential in the relationship of electrocardiographic ST-T abnormalities to risk of coronary death: 11.5 year follow-up findings of the Chicago Heart Association Detection Project in Industry. Circulation (1987) 1.08
Performance of the automated COBAS AMPLICOR system for the detection of hepatitis C virus RNA. Clin Diagn Virol (1997) 1.08
ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. Blood (1999) 1.07